422P Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in the phase III CASPIAN trial
comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.
Authors
- Gabriele Minuti (ORCID: https://orcid.org/0000-0003-2363-0446)
- Yashaswi Shrestha (ORCID: https://orcid.org/0000-0002-5567-0277)
- Haiyi Jiang (ORCID: https://orcid.org/0009-0002-8677-6821)
- Mingchao Xie (ORCID: https://orcid.org/0009-0006-7061-5483)
- L. Hendriks
- N. Donner
- C. Obrien
- A. Tufman
- L. Paz-Ares
- P. Chugh
- L. Landi
- M.R. Garcia Campelo
- A. D'Incecco
- D. Kauffmann-Guerrero
- J.W. Goldman
- A. La Salvia
- M.C. Garassino
- N. Reinmuth
- B. Resuli
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of California, Los Angeles (US)
- Istituto Superiore di Sanità (IT)
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- University of Chicago (US)
- AstraZeneca (South Korea) (KR)
- Hospital Universitario 12 De Octubre (ES)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- Asklepios Fachkliniken München-Gauting (DE)
- National Cancer Institute (MY)
- Complexo Hospitalario Universitario A Coruña (ES)
- AstraZeneca (United States) (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106736
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00